14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RDY vs TAK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TAK Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)
TAK Overall Winner
6-Pillar Tally: RDY 0 – 5 TAK (1 Tie)
Matrix Metrics: RDY 3 – 7 TAK
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Dr. Reddy's Laboratories Limited (RDY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RDY carries a Unified Composite Score of 34.7/100 (SELL) at $14.69 (31.6x Forward P/E, 9.1% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RDY vs TAK. Trailing 12-month operating profitability (RDY 9.1% vs TAK 16.6%) and valuation multiples (RDY 31.6x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $12.3B market capitalization and 9.1% operating margin.
OpEx & R&D Reinvestment40.4% of Rev ($1.43B)
90D Engineering Disclosures0 Published
TAK Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment48.2% of Rev ($12.4B)
90D Engineering Disclosures0 Published
Investor FAQ RDY vs TAK Key Questions & Quantitative Answers
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Dr. Reddy's Laboratories Limited (RDY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RDY carries a Unified Composite Score of 34.7/100 (SELL) at $14.69 (31.6x Forward P/E, 9.1% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Technically, RDY sits in a Markup phase (RSI 67.9, UNCLASSIFIED options structure) and TAK sits in a Markup phase (RSI 72.3, UNCLASSIFIED options structure).
TAK leads the Growth & Scale pillar: RDY posts -1.5% YoY revenue growth and -35.7% YoY earnings growth on $3.53B TTM revenue (49.5% gross margin, 9.1% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, RDY generates $3.53B in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, RDY deploys 40.4% of Rev ($1.43B) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.
TAK screens cheaper on headline valuation multiples. RDY trades at 31.6x Forward P/E, 41.0x Trailing P/E, 2.02x PEG, and 3.5x EV/Revenue (15.1% EBITDA margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RDY (7.3% ROE) versus TAK (0.6% ROE) capital efficiency.
In options market volatility and institutional positioning, RDY carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 24% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.